281 related articles for article (PubMed ID: 25936812)
1. Double-Blind, Placebo-Controlled Pilot Study of Processed Ultra Emu Oil Versus Placebo in the Prevention of Radiation Dermatitis.
Rollmann DC; Novotny PJ; Petersen IA; Garces YI; Bauer HJ; Yan ES; Wahner-Roedler D; Vincent A; Sloan JA; Issa Laack NN
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(3):650-8. PubMed ID: 25936812
[TBL] [Abstract][Full Text] [Related]
2. Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4.
Miller RC; Schwartz DJ; Sloan JA; Griffin PC; Deming RL; Anders JC; Stoffel TJ; Haselow RE; Schaefer PL; Bearden JD; Atherton PJ; Loprinzi CL; Martenson JA
Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1460-6. PubMed ID: 20800381
[TBL] [Abstract][Full Text] [Related]
3. A Randomized Trial of Mometasone Furoate 0.1% to Reduce High-Grade Acute Radiation Dermatitis in Breast Cancer Patients Receiving Postmastectomy Radiation.
Ho AY; Olm-Shipman M; Zhang Z; Siu CT; Wilgucki M; Phung A; Arnold BB; Porinchak M; Lacouture M; McCormick B; Powell SN; Gelblum DY
Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):325-333. PubMed ID: 29726361
[TBL] [Abstract][Full Text] [Related]
4. Natural oil-based emulsion containing allantoin versus aqueous cream for managing radiation-induced skin reactions in patients with cancer: a phase 3, double-blind, randomized, controlled trial.
Chan RJ; Mann J; Tripcony L; Keller J; Cheuk R; Blades R; Keogh S; Poole C; Walsh C
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):756-64. PubMed ID: 25151541
[TBL] [Abstract][Full Text] [Related]
5. A monocentric, open-label randomized standard-of-care controlled study of XONRID®, a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients.
Ingargiola R; De Santis MC; Iacovelli NA; Facchinetti N; Cavallo A; Ivaldi E; Dispinzieri M; Franceschini M; Giandini C; Romanello DA; Di Biaso S; Sabetti M; Locati L; Alfieri S; Bossi P; Guglielmo M; Macchi F; Lozza L; Valdagni R; Fallai C; Pignoli E; Orlandi E
Radiat Oncol; 2020 Aug; 15(1):193. PubMed ID: 32791985
[TBL] [Abstract][Full Text] [Related]
6. Randomized Double-blind Placebo-controlled Trial of Celecoxib for the Prevention of Skin Toxicity in Patients Receiving Radiation Therapy for Breast Cancer.
Ghasemi A; Danesh B; Yazdani-Charati J; Hosseinimehr SJ
Antiinflamm Antiallergy Agents Med Chem; 2018; 17(1):57-67. PubMed ID: 29651970
[TBL] [Abstract][Full Text] [Related]
7. Mometasone furoate cream reduces acute radiation dermatitis in patients receiving breast radiation therapy: results of a randomized trial.
Hindley A; Zain Z; Wood L; Whitehead A; Sanneh A; Barber D; Hornsby R
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):748-55. PubMed ID: 25585779
[TBL] [Abstract][Full Text] [Related]
8. Preemptive treatment with Xonrid®, a medical device to reduce radiation induced dermatitis in head and neck cancer patients receiving curative treatment: a pilot study.
Iacovelli NA; Naimo S; Bonfantini F; Cavallo A; Bossi P; Fallai C; Pignoli E; Alfieri S; Bergamini C; Favales F; Orlandi E
Support Care Cancer; 2017 Jun; 25(6):1787-1795. PubMed ID: 28108819
[TBL] [Abstract][Full Text] [Related]
9. Effects of topical timolol for the prevention of radiation-induced dermatitis in breast cancer: a pilot triple-blind, placebo-controlled trial.
Nabi-Meybodi M; Sahebnasagh A; Hakimi Z; Shabani M; Shakeri AA; Saghafi F
BMC Cancer; 2022 Oct; 22(1):1079. PubMed ID: 36266613
[TBL] [Abstract][Full Text] [Related]
10. Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a Phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4).
Neben-Wittich MA; Atherton PJ; Schwartz DJ; Sloan JA; Griffin PC; Deming RL; Anders JC; Loprinzi CL; Burger KN; Martenson JA; Miller RC
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):397-402. PubMed ID: 20888137
[TBL] [Abstract][Full Text] [Related]
11. Phase III double-blind evaluation of an aloe vera gel as a prophylactic agent for radiation-induced skin toxicity.
Williams MS; Burk M; Loprinzi CL; Hill M; Schomberg PJ; Nearhood K; O'Fallon JR; Laurie JA; Shanahan TG; Moore RL; Urias RE; Kuske RR; Engel RE; Eggleston WD
Int J Radiat Oncol Biol Phys; 1996 Sep; 36(2):345-9. PubMed ID: 8892458
[TBL] [Abstract][Full Text] [Related]
12. A case-control, mono-center, open-label, pilot study to evaluate the feasibility of therapeutic touch in preventing radiation dermatitis in women with breast cancer receiving adjuvant radiation therapy.
Younus J; Lock M; Vujovic O; Yu E; Malec J; D'Souza D; Stitt L
Complement Ther Med; 2015 Aug; 23(4):612-6. PubMed ID: 26275655
[TBL] [Abstract][Full Text] [Related]
13. Multicenter Randomized Double-Blind, Placebo-Controlled Trial GORTEC (Groupe Oncologie Radiotherapie Tete et Cou) 2009-01 Evaluating the Effect of the Regenerating Agent on Radiodermatitis of Head and Neck Cancer Patients.
Tao Y; Auperin A; Sire C; Martin M; Saliou MG; Bardet E; Sun XS; Chatellier T; Morand C; Cornely A; Angokai M; Di Rito A; Kichenin K; Blanchard P; D'Onofrio I; Bourhis J
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(3):590-595. PubMed ID: 29280453
[TBL] [Abstract][Full Text] [Related]
14. Topical Ectoin Versus Topical Dexpanthenol for Managing Acute Radiodermatitis Associated With Breast Cancer Radiotherapy: A Randomized Double-Blind Study.
Abd Elazim NE; Awad SM; El-Naggar MS; Mohamed RH
Dermatitis; 2023; 34(6):516-524. PubMed ID: 37792331
[No Abstract] [Full Text] [Related]
15. Topical hyaluronic acid vs. standard of care for the prevention of radiation dermatitis after adjuvant radiotherapy for breast cancer: single-blind randomized phase III clinical trial.
Pinnix C; Perkins GH; Strom EA; Tereffe W; Woodward W; Oh JL; Arriaga L; Munsell MF; Kelly P; Hoffman KE; Smith BD; Buchholz TA; Yu TK
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1089-94. PubMed ID: 22172912
[TBL] [Abstract][Full Text] [Related]
16. A phase 2 trial of once-weekly hypofractionated breast irradiation: first report of acute toxicity, feasibility, and patient satisfaction.
Dragun AE; Quillo AR; Riley EC; Roberts TL; Hunter AM; Rai SN; Callender GG; Jain D; McMasters KM; Spanos WJ
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):e123-8. PubMed ID: 23195779
[TBL] [Abstract][Full Text] [Related]
17. Topical use of phytotherapic cream (Capilen® cream) to prevent radiodermatitis in breast cancer: a prospective historically controlled clinical study.
Stefanelli A; Forte L; Medoro S; Sgualdo A; Lombardo D; Zini G; Maronta D; Rainieri E; Pascale G; Bagnolatti P; Colella M; Princivalle S; Fiorica F
G Ital Dermatol Venereol; 2014 Feb; 149(1):107-13. PubMed ID: 24566571
[TBL] [Abstract][Full Text] [Related]
18. A paired, double-blind, randomized comparison of a moisturizing durable barrier cream to 10% glycerine cream in the prophylactic management of postmastectomy irradiation skin care: trans Tasman Radiation Oncology Group (TROG) 04.01.
Graham PH; Plant N; Graham JL; Browne L; Borg M; Capp A; Delaney GP; Harvey J; Kenny L; Francis M; Zissiadis Y
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):45-50. PubMed ID: 23414763
[TBL] [Abstract][Full Text] [Related]
19. Melatonin for Prevention of Breast Radiation Dermatitis: A Phase II, Prospective, Double-Blind Randomized Trial.
Ben-David MA; Elkayam R; Gelernter I; Pfeffer RM
Isr Med Assoc J; 2016; 18(3-4):188-92. PubMed ID: 27228641
[TBL] [Abstract][Full Text] [Related]
20. Thêta-Cream versus Bepanthol lotion in breast cancer patients under radiotherapy. A new prophylactic agent in skin care?
Röper B; Kaisig D; Auer F; Mergen E; Molls M
Strahlenther Onkol; 2004 May; 180(5):315-22. PubMed ID: 15127162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]